Ondine to Participate in Vancouver General Hospital Infection Control Quality Improvement Project

 
TIDMOBP 
 
Ondine to Participate in Vancouver General Hospital Infection Control Quality Improvement Project 
 
FOR:  ONDINE BIOMEDICAL INC. 
 
TSX, AIM SYMBOL:  OBP 
 
April 15, 2011 
 
Ondine to Participate in Vancouver General Hospital Infection Control Quality Improvement Project 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 15, 2011) - Ondine Biomedical Inc. ("Ondine" or the "Company") 
(TSX:OBP)(AIM:OBP) today announced that it has agreed to supply Vancouver General Hospital (VGH) with Ondine's 
MRSAid(TM) Photodisinfection System for nasal pathogen decolonization as part of a thirteen month infection 
control Quality Improvement Project ("QIP") being conducted at the hospital. This project, championed by Dr. 
Elizabeth Bryce, Regional Medical Director, Infection Control, Vancouver Coastal Health, is being undertaken 
with the objective of reducing the incidence of surgical site infections (SSIs) in selected surgical 
populations. Patients treated under this initiative will include those undergoing cardiac, spinal, orthopedic, 
thoracic, vascular, breast reconstruction, and neurological surgeries. The QIP, which is being sponsored by VGH 
& UBC Hospital Foundation funding of approximately $675,000, will focus on pre-surgical pathogen decolonization 
using photodisinfection of the nasal passages and full body chlorhexidine wipes for all patients treated under 
this initiative. 
 
"We are excited to be collaborating on this QIP which will utilize MRSAid(TM), Ondine's non-antibiotic nasal 
pathogen decolonization system," stated Dr Bryce. "Surgical site infections are responsible for longer patient 
recovery times and significant costs to the health care system. In certain cases, these infections can result 
in patient mortality due to the presence of highly antibiotic resistant pathogens." 
 
Dr. Cale Street of Ondine stated: "Photodisinfection provides a rapid, powerful antibacterial modality that 
does not generate bacterial resistance. The 10 minute, simple, painless MRSAid(TM) procedure is undertaken at 
the hospital at the time of preparation for surgery, and represents a promising approach to decolonization of 
acute care patients in healthcare facility settings. The MRSAid(TM) Photodisinfection System is designed to 
reduce hospital-acquired infections among high risk patients while eliminating patient compliance and 
antibiotic resistance concerns associated with currently used topical antibiotics." 
 
About Ondine Biomedical Inc. 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection 
provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic 
resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development 
laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: 
www.ondinebio.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biomedical Inc. 
Carolyn Cross 
Chairman and CEO 
[e-mail] 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited, Nominated Adviser 
Mark Williams/Bhavesh Patel 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
 
Ondine Biomedical Inc.